IMRX
Immuneering Corporation
There isn't enough reported data to score IMRX yet.
IMRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
IMRX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
IMRX PE Valuation
IMRX has no meaningful PE right now: it lost money over the past year.
IMRX Forward outlook
There aren't enough analyst estimates for IMRX to show an outlook.
IMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.14 | +$0.65 |
| Q2 2026 | -$1.15 | +$0.75 |
| Q1 2026 | -$1.28 | +$0.69 |
| Q4 2025 | -$1.49 | +$0.55 |
| Q3 2025 | -$1.79 | +$0.17 |
| Q2 2025 | -$1.90 | $0.00 |
| Q1 2025 | -$1.97 | -$0.11 |
| Q4 2024 | -$2.04 | -$0.16 |
IMRX is still losing money, but far less than before: $1.14 per share over the past year, against $2.97 at its worst in late 2021.
IMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $455 | -100% |
| Q3 2022 | $38.4K | -92% |
| Q2 2022 | $94.4K | -86% |
| Q1 2022 | $183.7K | -75% |
| Q4 2021 | $189.6K | -71% |
| Q3 2021 | $482.1K | -29% |
| Q2 2021 | $660K | +37% |
| Q1 2021 | $748.2K | +55% |
IMRX's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -3073628% | -3067765 points |
| Q3 2022 | -34362% | -32590 points |
| Q2 2022 | -12334% | -11124 points |
| Q1 2022 | -7036% | -6203 points |
| Q4 2021 | -5863% | -4986 points |
| Q3 2021 | -1772% | -1127 points |
| Q2 2021 | -1211% | -461 points |
| Q1 2021 | -833% | -163 points |
IMRX's operating margin was −3073628% last quarter, down 3067765 points from the same quarter a year ago, near the bottom of its range since 2020.
IMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.8M | -$4.8M |
| Q2 2026 | -$16.5M | -$7.1M |
| Q1 2026 | -$18.5M | -$4.4M |
| Q4 2025 | -$10M | +$4.6M |
| Q3 2025 | -$12M | +$1.5M |
| Q2 2025 | -$9.4M | +$2.1M |
| Q1 2025 | -$14.1M | +$1.4M |
| Q4 2024 | -$14.5M | -$2.6M |
IMRX has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
IMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +17K shares |
| 1 year | +63% | +25M shares |
| 3 years | +121% | +35.4M shares |
| 5 years | +1206% | +59.8M shares |
| Available history | +379% | +51.2M shares |
IMRX has 65M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IMRX Net Leverage
IMRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 16.4 | Oversold |
IMRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
IMRX PE vs Healthcare Sector
IMRX has no meaningful PE right now: it lost money over the past year.
IMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.84 | 4.4% below |
| 20 week MA | $4.38 | 16% below |
| 50 week MA | $4.91 | 25% below |
| 100 week MA | $4.24 | 13% below |
| 200 week MA | $4.78 | 23% below |
IMRX is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
IMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.6 | $20.5 | +17% |
| 2022 | $20.5 | $4.37 | -79% |
| 2023 | $4.37 | $7.35 | +68% |
| 2024 | $7.35 | $2.33 | -68% |
| 2025 | $2.33 | $6.73 | +189% |
| 2026 YTD | $6.73 | $3.67 | -45% |
IMRX's yearly returns have swung widely, from +189% in 2025 to −79% in 2022. It's down 45% so far in 2026.